5F-CUMYL-PINACA also recognized as SGT-25 and occasionally marketed in e-cigarette form as C-Liquid, belongs to the category of indazole-3-carboxamide-based synthetic cannabinoids. It exerts its action as a potent agonist on cannabinoid receptors, with the original patent asserting approximately fourfold selectivity for CB1. It exhibits an EC50 of less than 0.1 nM for human CB1 receptors and 0.37 nM for human CB2 receptors.
In more recent assessments employing diverse techniques, 5F-CUMYL-PINACA displayed varying EC50 values, such as 0.43 nM at CB1 and 11.3 nM at CB2, indicating a somewhat elevated CB1 selectivity of 26 times. Alternatively, it was measured at 15.1 nM at CB1 and 34.8 nM at CB2 with only 2.3 times selectivity. However, it’s important to note that these figures cannot be directly compared due to the distinct assay techniques utilized in each case.

IUPAC name
CAS Number1400742-16-6 
PubChem CID86274158
Chemical and physical data
Molar mass367.468 g·mol−1

Legal status

In the United States, the DEA temporarily emergency scheduled 5F-CUMYL-PINACA in 2019, subsequently designating it as a permanent Schedule I Controlled Substance on April 7, 2022. On a different note, Sweden’s public health agency recommended categorizing 5F-CUMYL-PINACA as a hazardous substance on November 10, 2014.


1. What is 5F-CUMYL-PINACA?

  • 5F-CUMYL-PINACA is a synthetic cannabinoid known for its psychoactive effects. It is sometimes referred to as SGT-25 and is occasionally sold as C-Liquid.

2. How does 5F-CUMYL-PINACA work?

  • 5F-CUMYL-PINACA acts as an agonist on cannabinoid receptors, particularly CB1 and CB2 receptors, leading to various physiological and psychological effects.

3. Is 5F-CUMYL-PINACA legal in the United States?

  • No, 5F-CUMYL-PINACA is classified as a Schedule I Controlled Substance in the United States, making its possession, distribution, and use illegal.

4. What are the effects of 5F-CUMYL-PINACA use?

  • The effects of 5F-CUMYL-PINACA use may include altered perception, relaxation, increased heart rate, and, in some cases, adverse reactions like anxiety and hallucinations.

5. Are there health risks associated with 5F-CUMYL-PINACA?

  • Yes, like many synthetic cannabinoids, 5F-CUMYL-PINACA can pose health risks, including potential cardiovascular and psychological complications. Long-term use and high doses can be particularly dangerous.

6. Is 5F-CUMYL-PINACA banned in other countries?

  • Yes, 5F-CUMYL-PINACA is banned or controlled in several countries. It’s essential to be aware of the legal status of this substance in your region.

7. How can I stay safe regarding 5F-CUMYL-PINACA use?

  • The best way to stay safe is to avoid using synthetic cannabinoids like 5F-CUMYL-PINACA altogether, as their safety and purity are often uncertain. If you have concerns about substance use, seek assistance from a healthcare professional.

8. Can 5F-CUMYL-PINACA be detected in drug tests?

  • Yes, 5F-CUMYL-PINACA can be detected in drug tests designed to identify synthetic cannabinoids. It’s essential to be aware that using this substance can have legal and employment consequences.

9. Is there ongoing research on 5F-CUMYL-PINACA?

  • Research on synthetic cannabinoids, including 5F-CUMYL-PINACA, is ongoing to understand their effects and potential risks better. However, it is crucial to note that recreational use of these substances is strongly discouraged.

10. Where can I find help if I or someone I know is struggling with substance use?

  • If you or someone you know is dealing with substance use issues, consider reaching out to local healthcare providers, addiction treatment centers, or support groups for guidance and assistance. Your well-being is a priority, and help is available.


  1. In a publication dated November 13, 2018, titled “Comprehensive Characterization of 5F-Cumyl-PINACA in ‘E-Liquids’ for Electronic Cigarettes,” the authors Angerer V, Franz F, Moosmann B, Bisel P, and Auwärter V delve into the realm of synthetic cannabinoids, shedding light on a trendy product. Their study encompasses an extensive investigation into the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. The findings of this research are documented in the journal “Forensic Toxicology,” Volume 37, Issue 1, pages 186–196, with a DOI of 10.1007/s11419-018-0451-8. This study is further supported by PMC 6315005 and can be located through PMID 30636986.
  2. For a reference to “5-fluoro CUMYL-PINACA (CRM),” Cayman Chemical provides information. This reference was accessed on November 22, 2018.
  3. A patent application from April 11, 2013, titled “Cannabinoid Compounds,” authored by Bowden and others, is registered under New Zealand Patent application 623626. The application can be referenced with an access date of November 22, 2018.
  4. In October 2017, Longworth M, Banister SD, Boyd R, Kevin RC, Connor M, McGregor IS, and Kassiou M explored the pharmacology of Cumyl-Carboxamide Synthetic Cannabinoids, particularly NPS (New Psychoactive Substances) such as CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. The results of their research can be found in “ACS Chemical Neuroscience,” Volume 8, Issue 10, spanning pages 2159–2167, and can be cited using the DOI 10.1021/acschemneuro.7b00267, as well as the PMID 28792725.
  5. Asada A, Doi T, Tagami T, Takeda A, Satsuki Y, Kawaguchi M, Nakamura A, and Sawabe Y explored the “Cannabimimetic Activities of Cumyl Carboxamide-Type Synthetic Cannabinoids” in a publication in the journal “Forensic Toxicology,” Volume 36, Issue 1, with pages 170–177. The reference for this study includes the DOI 10.1007/s11419-017-0374-9 and the S2CID 7996915.
  6. On April 16, 2019, the Federal Register announced the “Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I.”
  7. In the Federal Register, Issue 87 (67), dated April 7, 2022, it was noted that “Schedules of Controlled Substances: Placement of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I.”
  8. The Public Health Agency of Sweden, in a statement dated November 10, 2014, suggested the classification of cannabinoids as a health-endangering substance. This information is available in Swedish and can be cited as “Cannabinoids suggested classified as health endangering substance.”

Leave a Comment

Your email address will not be published. Required fields are marked *